CORT - CIK 0001088856
CORCEPT THERAPEUTICS INC trades as CORT and has a market capitalization of $8.39 B, making it the #1039 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $761.41M, up 12.8% from the prior year and net income of $99.65M. This page tracks CORCEPT THERAPEUTICS INC through 1,955 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years CORCEPT THERAPEUTICS INC's revenue grew from $81.32M to $761.41M, a compound annual growth rate of 28.2%. Net profit margin expanded from 10.0% to 13.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-20 |
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure – Corcept Therapeutics, Incorporated
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome – Corcept Therapeutics, Incorporated
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update – Corcept Therapeutics, Incorporated
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis – Corcept Therapeutics, Incorporated
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call – Corcept Therapeutics, Incorporated
The largest companies sharing CORCEPT THERAPEUTICS INC's SEC industry classification (pharmaceutical preparations).
CORCEPT THERAPEUTICS INC (CORT) has a market capitalization of $8.39 B as of 2026-06-10, ranking #1039 among US-listed companies.
CORCEPT THERAPEUTICS INC reported revenue of $761.41M for fiscal year 2025, an increase of 12.8% year over year.
Yes. CORCEPT THERAPEUTICS INC reported net income of $99.65M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.